96901-92-7

Basic information

• Product Name: 3-AMINO-8-BENZYL-8-AZABICYCLO[3.2.1]OCTANE
• Synonyms: 3-AMINO-8-BENZYL-8-AZABICYCLO[3.2.1]OCTANE
• CAS NO: 96901-92-7
• Molecular Formula: C₁₄H₂₀N₂
• Molecular Weight: 216.32
• Mol File: 96901-92-7.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: 3-AMINO-8-BENZYL-8-AZABICYCLO[3.2.1]OCTANE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-AMINO-8-BENZYL-8-AZABICYCLO[3.2.1]OCTANE(96901-92-7)
• EPA Substance Registry System: 3-AMINO-8-BENZYL-8-AZABICYCLO[3.2.1]OCTANE(96901-92-7)

Safety Data

• Hazardous Substances Data: 96901-92-7(Hazardous Substances Data)

Usage

Description

3-AMINO-8-BENZYL-8-AZABICYCLO[3.2.1]OCTANE is a bicyclic chemical compound that features an amino group and a benzyl group. It is a member of the azabicyclic compounds class, which are recognized for their wide range of biological activities. This particular compound is of interest in medicinal chemistry, especially for the development of drugs that target the central nervous system. Its distinctive structural attributes position it as a potential candidate for creating pharmaceuticals with specific pharmacological characteristics. Further investigation into its chemical and biological properties could pave the way for the creation of innovative therapeutic agents to address a variety of diseases and conditions.

Uses

Used in Pharmaceutical Industry:
3-AMINO-8-BENZYL-8-AZABICYCLO[3.2.1]OCTANE is used as a starting material or intermediate in the synthesis of pharmaceutical agents for the central nervous system. Its unique structure allows for the development of drugs that can potentially treat neurological disorders and conditions.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 3-AMINO-8-BENZYL-8-AZABICYCLO[3.2.1]OCTANE serves as a compound of interest for research into its chemical properties and potential interactions with biological targets. This research can lead to a better understanding of its therapeutic potential and the design of new drugs with improved efficacy and safety profiles.
Used in Drug Design and Development:
3-AMINO-8-BENZYL-8-AZABICYCLO[3.2.1]OCTANE is utilized in the design and development of novel therapeutic agents. Its structural features can be modified to create a variety of drug candidates that can be tested for their effectiveness in treating specific diseases and conditions.

Upstream product

• 28957-72-4 N-benzyltropinone 
• 5632-84-8 nortropinone 
• 542-05-2 acetonedicarboxylic acid 
• 100-46-9 benzylamine 
• 877457-32-4 3-azido-8-benzyl-8-aza-bicyclo[3.2.1]octane 
• 76272-34-9 8-benzyl-8-azabicyclo[3.2.1] octan-3-one oxime 

Downstream Products

• 1174851-96-7 8-benzyl-N-(2-nitrophenyl)-8-azabicyclo[3.2.1]octan-3-amine 
• 753013-75-1 N-(8-benzyl-8-aza-bicyclo[3.2.1]oct-3-yl)-3,4-dichloro-benzamide 
• 287114-24-3 (8-benzyl-8-aza-bicyclo[3.2.1]oct-3-yl)-carbamic acid tert-butyl ester 
• 1313481-28-5 N-(8-benzyl-8-aza-bicyclo[3.2.1]octan-3-yl)-6-chloro-2-methoxyacridin-9-amine 

Relevant articles and documents

Structure-Based Design and Development of Chemical Probes Targeting Putative MOR-CCR5 Heterodimers to Inhibit Opioid Exacerbated HIV-1 Infectivity

Crystal structures of ligand-bound G-protein-coupled receptors provide tangible templates for rationally designing molecular probes. Herein, we report the structure-based design, chemical synthesis, and biological investigations of bivalent ligands targeting putative mu opioid receptor C-C motif chemokine ligand 5 (MOR-CCR5) heterodimers. The bivalent ligand VZMC013 possessed nanomolar level binding affinities for both the MOR and CCR5, inhibited CCL5-stimulated calcium mobilization, and remarkably improved anti-HIV-1BaL activity over previously reported bivalent ligands. VZMC013 inhibited viral infection in TZM-bl cells coexpressing CCR5 and MOR to a greater degree than cells expressing CCR5 alone. Furthermore, VZMC013 blocked human immunodeficiency virus (HIV)-1 entry in peripheral blood mononuclear cells (PBMC) cells in a concentration-dependent manner and inhibited opioid-accelerated HIV-1 entry more effectively in phytohemagglutinin-stimulated PBMC cells than in the absence of opioids. A three-dimensional molecular model of VZMC013 binding to the MOR-CCR5 heterodimer complex is constructed to elucidate its mechanism of action. VZMC013 is a potent chemical probe targeting MOR-CCR5 heterodimers and may serve as a pharmacological agent to inhibit opioid-exacerbated HIV-1 entry.

Anti-prion activities and drug-like potential of functionalized quinacrine analogs with basic phenyl residues at the 9-amino position

In this paper, we report the synthesis and cell-based anti-prion activity of quinacrine analogs derived by replacing the basic alkyl side chain of quinacrine with 4-(4-methylpiperazin-I-yl)phenyl, (1-benzylpiperidin-4-yl) and their structural variants. Several promising analogs were found that have a more favorable anti-prion profile than quinacrine in terms of potency and activity across different prion-infected murine cell models. They also exhibited greater binding affinities for a human prion protein fragment (hPrP121-231) than quinacrine, and had permeabilities on the PAMPA-BBB assay that fall within the range of CNS permeant candidates. When evaluated on bidirectional assays on a Pgp overexpressing cell line, one analog was less susceptible to Pgp efflux activity compared to quinacrine. Taken together, the results point to an important role for the substituted 9-amino side chain attached to the acridine, tetrahydroacridine and quinoline scaffolds. The nature of this side chain influenced cell-based potency, PAMPA permeability and binding affinity to hPrP121-231.

NOVEL HYDROXYCOUMARANONE DERIVATIVES AS ANTITUMOR AND ANTIMETASTATIC AGENTS WITH IMPROVED BIOLOGICAL ACTIVITY IN CELLULAR ASSAYS AND IMPROVED STABILITY

The present invention relates to new compounds of the general formula (I) or (II), their pharmaceutically acceptable salts as well as their enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments c